Furthermore, we summarize recent promising oral therapies in diabetes; fenofibrate and pemafibrate, well-known agonists of peroxisome proliferator-activated receptor alpha (PPARα) in treatments for dyslipidemia [10] and discuss their recent potentials as promising oral DR treatments. Here, PPARA is linked to diabetes mellitus.